145195-63-7 Usage
Description
CIS-ENTACAPONE, also known as the (Z)-Isomer of Entacapone polymorphic form B, is a metabolite of the catechol-O-methyltransferase (COMT) inhibitor entacapone. It is characterized as an orange solid and is recognized for its potential as an impurity in commercial preparations of entacapone, as well as a degradant formed by UV light exposure. CIS-ENTACAPONE plays a significant role in the treatment of Parkinson's disease due to its antiparkinsonian properties.
Uses
Used in Pharmaceutical Industry:
CIS-ENTACAPONE is used as an antiparkinsonian agent for the treatment of Parkinson's disease. It functions by inhibiting the enzyme catechol-O-methyltransferase (COMT), which is responsible for the breakdown of dopamine in the brain. By reducing the degradation of dopamine, CIS-ENTACAPONE helps to increase its levels, thereby alleviating the symptoms of Parkinson's disease and improving the patient's motor function.
Additionally, CIS-ENTACAPONE may be used as a potential impurity in the quality control and assessment of commercial entacapone preparations. Its presence can be monitored and controlled to ensure the safety, efficacy, and quality of the medication.
In the field of pharmaceutical research and development, CIS-ENTACAPONE serves as a valuable compound for studying the effects of COMT inhibition and its implications in the treatment of Parkinson's disease. This knowledge can be applied to the development of new drugs and therapies for the management of this neurodegenerative disorder.
Check Digit Verification of cas no
The CAS Registry Mumber 145195-63-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,5,1,9 and 5 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 145195-63:
(8*1)+(7*4)+(6*5)+(5*1)+(4*9)+(3*5)+(2*6)+(1*3)=137
137 % 10 = 7
So 145195-63-7 is a valid CAS Registry Number.
145195-63-7Relevant articles and documents
DENGUE AND WEST NILE VIRUS PROTEASE INHIBITORS
-
Page/Page column 29-30, (2014/10/18)
Compounds and methods of treating or preventing a Flavivirus infection in a subject are provided. The methods comprise administering to the subject a therapeutically effective amount of a compound as described herein. The methods are useful in treating and/or preventing Flavivirus infections such as, for example, West Nile Virus, Dengue Virus, and Japanese Encephalitis Virus. Methods of inhibiting a Flavivirus protease in a cell are also provided.
PROCESS AND PRODUCT
-
Page/Page column 9, (2008/06/13)
The present invention relates to an improved process for isolation and purification of Entacapone, pharmaceutical compositions and therapeutic uses thereof. The process provides an improved yield and improved isomeric purity of produced Entacapone.
PROCESS FOR MANUFACTURING ENTACAPONE
-
Page/Page column 9-11, (2008/06/13)
A new process for manufacturing entacapone comprising reacting 3,4-dihydroxy-5-nitrobenzaldehyde with N,N-diethyl-2-cyanoacetamide in the presence of a catalyst in a C 4 to 8 alcohol at reduced pressure and at a temperature of at least 70 °C, cooling the mixture to a temperature of 30 °C or below, seeding the mixture with N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide comprising at least 10 % of the Z-isomer by weight in the seeding crystals, cooling the mixture to a temperature of 5 °C or below, isolating the crystallized product and converting the obtained mixture of the E- and Z-isomers of N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide to the E-isomer (entacapone).
